Skinvisible (SKVI) Net Income Growth (1y) (2011 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Net Income Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.12 Bn | 626.36 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 440.93 Bn | 434.36 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 364.34 Bn | 357.20 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 268.31 Bn | 260.62 Bn | 11.24 Bn | 4.82% |
| 5 | Pfizer | 158.49 Bn | 146.79 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.52 Bn | 45.14 Bn | 10.79 Bn | -58.94% |
| 7 | Revolution Medicines | 44.27 Bn | 44.27 Bn | - | - |
| 8 | Incyte | 25.01 Bn | 20.47 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.18 Bn | 18.51 Bn | 683.80 Mn | 7.59% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 8.40% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.40% |
| Mar 31, 2026 | 4.92% |
| Dec 31, 2025 | 29.68% |
| Sep 30, 2025 | 14.51% |
| Jun 30, 2025 | 9.81% |
| Mar 31, 2025 | 3.23% |
| Dec 31, 2024 | -20.94% |
| Sep 30, 2024 | -1.81% |
| Jun 30, 2024 | -10.33% |
| Mar 31, 2024 | 80.83% |
| Dec 31, 2023 | 25.70% |
| Sep 30, 2023 | 31.27% |
| Jun 30, 2023 | -36.78% |
| Mar 31, 2023 | -310.46% |
| Dec 31, 2022 | 11.43% |
| Sep 30, 2022 | -105.72% |
| Jun 30, 2022 | 23.67% |
| Mar 31, 2022 | 15.25% |
| Dec 31, 2021 | -56.51% |
| Sep 30, 2021 | 50.37% |